IRIDEX (IRIX)
Market Price (9/21/2026): $0.6503 | Market Cap: $11.3 MilSector: Health Care | Industry: Life Sciences Tools & Services
IRIDEX (IRIX)
Market Price (9/21/2026): $0.6503Market Cap: $11.3 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -32% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, Diabetes Management, Show more. | Weak multi-year price returns2Y Excs Rtn is -103%, 3Y Excs Rtn is -134% | Penny stockMkt Price is 0.7 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5.4% Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -2.7%, Rev Chg QQuarterly Revenue Change % is -7.4% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -3.4%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3.9% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -35% Key risksIRIX key risks include [1] a high probability of bankruptcy driven by persistent operational losses and the need for additional funding, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -32% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, Diabetes Management, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -103%, 3Y Excs Rtn is -134% |
| Penny stockMkt Price is 0.7 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5.4% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -2.7%, Rev Chg QQuarterly Revenue Change % is -7.4% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -3.4%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3.9% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -35% |
| Key risksIRIX key risks include [1] a high probability of bankruptcy driven by persistent operational losses and the need for additional funding, Show more. |
Qualitative Assessment
AI Analysis | Feedback
IRIDEX (IRIX) stock has lost about 35% since 5/31/2026 because of the following key factors:
1. Fiscal Q2 2026 Revenue Miss and Widened Net Loss.
IRIDEX reported a 7% year-over-year decrease in total revenue for its fiscal second quarter ended July 4, 2026, reaching $12.6 million, which missed analyst estimates by approximately $0.99 million to $1.02 million. Concurrently, the company's net loss widened to $1.3 million, or $0.07 per share, compared to a net loss of $1.0 million, or $0.06 per share, in the prior-year period, missing analyst EPS estimates by $0.06.
2. Significant Decline in Retina Product Revenue.
The overall revenue decline was largely driven by a substantial 19% year-over-year decrease in retina product revenue, which fell to $6.5 million in fiscal Q2 2026 from $8.0 million in the comparable period of the prior year. This decline was attributed to "temporary, external headwinds—including international commercial transitions and regulatory approval related factors," as well as disruptions in the Middle East and reduced sell-through in China.
Show more
IRIDEX (IRIX) stock has lost about 35% since 5/31/2026 because of the following key factors:
1. Fiscal Q2 2026 Revenue Miss and Widened Net Loss.
IRIDEX reported a 7% year-over-year decrease in total revenue for its fiscal second quarter ended July 4, 2026, reaching $12.6 million, which missed analyst estimates by approximately $0.99 million to $1.02 million. Concurrently, the company's net loss widened to $1.3 million, or $0.07 per share, compared to a net loss of $1.0 million, or $0.06 per share, in the prior-year period, missing analyst EPS estimates by $0.06.
2. Significant Decline in Retina Product Revenue.
The overall revenue decline was largely driven by a substantial 19% year-over-year decrease in retina product revenue, which fell to $6.5 million in fiscal Q2 2026 from $8.0 million in the comparable period of the prior year. This decline was attributed to "temporary, external headwinds—including international commercial transitions and regulatory approval related factors," as well as disruptions in the Middle East and reduced sell-through in China.
3. Nasdaq Minimum Bid Price Deficiency.
On September 2, 2026, IRIDEX received a notice from Nasdaq indicating that the company was not in compliance with the minimum bid price requirement of $1.00 per share for continued listing. This deficiency, coupled with the stock trading near its 52-week low of $0.65, raised concerns about the company's listing status and contributed to negative investor sentiment.
4. Overall Revenue Weakness Despite Glaucoma Segment Growth.
Despite positive performance in its glaucoma business, with Cyclo G6 product family revenue increasing by 19% year-over-year to $3.9 million, driven by a 35% surge in probe volume, the strong performance was insufficient to offset the significant weakness in the retina segment, resulting in a net 7% decline in total revenue for fiscal Q2 2026. This highlights the disproportionate impact of the retina segment's underperformance on the company's overall financial results.
Show less
Stock Movement Drivers
Fundamental Drivers
The -36.2% change in IRIX stock from 5/31/2026 to 9/20/2026 was primarily driven by a -34.5% change in the company's P/S Multiple.| (LTM values as of) | 5312026 | 9202026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.05 | 0.67 | -36.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 53 | 52 | -1.9% |
| P/S Multiple | 0.3 | 0.2 | -34.5% |
| Shares Outstanding (Mil) | 17 | 17 | -0.6% |
| Cumulative Contribution | -36.2% |
Market Drivers
5/31/2026 to 9/20/2026| Return | Correlation | |
|---|---|---|
| IRIX | -36.2% | |
| Market (SPY) | 0.9% | 7.8% |
| Sector (XLV) | 12.7% | -24.6% |
Fundamental Drivers
The -52.1% change in IRIX stock from 2/28/2026 to 9/20/2026 was primarily driven by a -51.9% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 9202026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.40 | 0.67 | -52.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 51 | 52 | 1.8% |
| P/S Multiple | 0.5 | 0.2 | -51.9% |
| Shares Outstanding (Mil) | 17 | 17 | -2.3% |
| Cumulative Contribution | -52.1% |
Market Drivers
2/28/2026 to 9/20/2026| Return | Correlation | |
|---|---|---|
| IRIX | -52.1% | |
| Market (SPY) | 11.6% | 17.7% |
| Sector (XLV) | 5.5% | -5.3% |
Fundamental Drivers
The -50.0% change in IRIX stock from 8/31/2025 to 9/20/2026 was primarily driven by a -50.0% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 9202026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.34 | 0.67 | -50.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 50 | 52 | 3.7% |
| P/S Multiple | 0.5 | 0.2 | -50.0% |
| Shares Outstanding (Mil) | 17 | 17 | -3.6% |
| Cumulative Contribution | -50.0% |
Market Drivers
8/31/2025 to 9/20/2026| Return | Correlation | |
|---|---|---|
| IRIX | -50.0% | |
| Market (SPY) | 19.4% | 18.1% |
| Sector (XLV) | 24.1% | 3.8% |
Fundamental Drivers
The -59.6% change in IRIX stock from 8/31/2023 to 9/20/2026 was primarily driven by a -52.1% change in the company's P/S Multiple.| (LTM values as of) | 8312023 | 9202026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.66 | 0.67 | -59.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 56 | 52 | -8.5% |
| P/S Multiple | 0.5 | 0.2 | -52.1% |
| Shares Outstanding (Mil) | 16 | 17 | -7.9% |
| Cumulative Contribution | -59.6% |
Market Drivers
8/31/2023 to 9/20/2026| Return | Correlation | |
|---|---|---|
| IRIX | -59.6% | |
| Market (SPY) | 75.6% | 17.1% |
| Sector (XLV) | 32.3% | 9.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| IRIX Return | 143% | -67% | 40% | -40% | -32% | -43% | -74% |
| Peers Return | 19% | -20% | -8% | -19% | 37% | 8% | 5% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| IRIX Win Rate | 58% | 25% | 50% | 25% | 33% | 44% | |
| Peers Win Rate | 60% | 50% | 48% | 42% | 54% | 58% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| IRIX Max Drawdown | -40% | -69% | -46% | -61% | -57% | -61% | |
| Peers Max Drawdown | -29% | -44% | -49% | -37% | -37% | -43% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: A, TECH, ATEC, CERS, FRNM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/18/2026 (YTD)
How Low Can It Go
| Event | IRIX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -47.0% | -18.8% |
| % Gain to Breakeven | 88.6% | 23.1% |
| Time to Breakeven | 130 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -12.0% | -7.8% |
| % Gain to Breakeven | 13.6% | 8.5% |
| Time to Breakeven | 14 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -35.4% | -9.5% |
| % Gain to Breakeven | 54.9% | 10.5% |
| Time to Breakeven | 31 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -24.3% | -6.7% |
| % Gain to Breakeven | 32.1% | 7.1% |
| Time to Breakeven | 108 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -58.9% | -33.7% |
| % Gain to Breakeven | 143.6% | 50.9% |
| Time to Breakeven | 295 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -36.4% | -19.2% |
| % Gain to Breakeven | 57.1% | 23.8% |
| Time to Breakeven | 789 days | 105 days |
In The Past
IRIDEX's stock fell -47.0% during the 2025 US Tariff Shock. Such a loss loss requires a 88.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | IRIX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -47.0% | -18.8% |
| % Gain to Breakeven | 88.6% | 23.1% |
| Time to Breakeven | 130 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -35.4% | -9.5% |
| % Gain to Breakeven | 54.9% | 10.5% |
| Time to Breakeven | 31 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -24.3% | -6.7% |
| % Gain to Breakeven | 32.1% | 7.1% |
| Time to Breakeven | 108 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -58.9% | -33.7% |
| % Gain to Breakeven | 143.6% | 50.9% |
| Time to Breakeven | 295 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -36.4% | -19.2% |
| % Gain to Breakeven | 57.1% | 23.8% |
| Time to Breakeven | 789 days | 105 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -23.2% | -17.9% |
| % Gain to Breakeven | 30.2% | 21.8% |
| Time to Breakeven | 112 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -23.1% | -15.4% |
| % Gain to Breakeven | 30.1% | 18.2% |
| Time to Breakeven | 240 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -76.5% | -53.4% |
| % Gain to Breakeven | 325.5% | 114.4% |
| Time to Breakeven | 127 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -41.7% | -8.6% |
| % Gain to Breakeven | 71.4% | 9.5% |
| Time to Breakeven | 28 days | 47 days |
In The Past
IRIDEX's stock fell -47.0% during the 2025 US Tariff Shock. Such a loss loss requires a 88.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About IRIDEX (IRIX)
IRIDEX Corporation (IRIX) is an ophthalmic medical technology company that specializes in developing and marketing therapeutic-based laser systems, delivery devices, and consumable instrumentation. The company's primary focus is to provide advanced solutions for ophthalmologists to treat a variety of sight-threatening eye diseases, thereby helping to preserve and restore vision.
The company's core product offerings include a range of laser consoles such as the Cyclo G6 system, specifically designed for glaucoma treatment, and the IQ 532/577 and OcuLight series, which address conditions like diabetic macular edema, other retinal diseases, and proliferative diabetic retinopathy. Alongside these systems, IRIDEX offers critical delivery devices, including the TxCell scanning laser delivery system, and specialized probes like the MicroPulse P3 for MicroPulse transscleral laser therapy, the G-Probes for refractory glaucoma, and the EndoProbe family for vitrectomy procedures.
IRIDEX serves a diverse customer base primarily within the eye care sector, including ophthalmologists, research and teaching hospitals, surgical centers, general hospitals, and office clinics. The company markets its products through a direct sales force in the United States and extends its reach internationally through a network of independent distributors, ensuring its specialized technologies are accessible to a global market of eye care professionals.
AI Analysis | Feedback
- Stryker for eye surgery lasers.
- Medtronic for ophthalmic laser treatments.
AI Analysis | Feedback
Major Products of IRIDEX (IRIX)
- Cyclo G6 laser system: A therapeutic laser system specifically designed for the treatment of glaucoma.
- IQ 532 and IQ 577 laser photocoagulation systems: Laser systems used for the treatment of diabetic macular edema and other retinal diseases.
- OcuLight laser photocoagulation systems: A family of laser systems (including TX, SL, SLx, GL, GLx models) used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
- TxCell scanning laser delivery system: A delivery system enabling physicians to perform multi-spot pattern scanning during laser treatments.
- Slit lamp adapter: A device that allows physicians to integrate a standard slit lamp into diagnosis and treatment procedures.
- Laser indirect ophthalmoscope: A delivery device used for procedures treating peripheral retinal disorders.
- MicroPulse P3 Probe: A consumable probe designed for use with the Cyclo G6 laser system to perform MicroPulse transscleral laser therapy.
- G-Probe and G-Probe Illuminate: Probes utilized in procedures to treat uncontrolled and refractory glaucoma.
- EndoProbe family of products: A line of probes specifically developed for use in vitrectomy procedures.
AI Analysis | Feedback
IRIDEX (IRIX) sells its ophthalmic medical technology primarily to other companies and institutions within the healthcare sector, not directly to individual consumers. The company's customer base consists of a diverse range of professional and institutional buyers globally. The provided background information does not list specific named customer companies, but rather categories of entities that utilize their products. Therefore, IRIDEX's major customers fall into the following categories:
- Ophthalmologists (operating within private practices or clinics)
- Research and teaching hospitals
- Government installations
- Surgical centers
- Hospitals
- Veterinary practices
- Office clinics
As these are categories of customers rather than specific named public companies, no stock symbols can be provided.
AI Analysis | Feedback
AI Analysis | Feedback
Patrick Mercer
President & Chief Executive Officer
Mr. Mercer was appointed as President and Chief Executive Officer of IRIDEX Corporation effective October 1, 2024. He previously served as the company's Chief Operating Officer and President. Mr. Mercer joined IRIDEX in 2018, bringing over 20 years of experience in operational positions within the medical device industry. Prior to joining IRIDEX, he was the Chief Operating Officer of Tracknet, a privately held LoRaWAN Internet of Things (IoT) solutions provider. His experience also includes leadership roles at privately held RODO Medical and DFINE. Mr. Mercer has global experience managing manufacturing operations in various countries including Hungary, China, Korea, Costa Rica, Germany, and Australia.
Romeo R. Dizon
Chief Financial Officer
Mr. Dizon has served as Chief Financial Officer of IRIDEX Corporation since March 2025. He previously held roles within IRIDEX from 2008 to 2020, including Controller, Vice President of Finance, and Interim Chief Financial Officer. Mr. Dizon possesses over 35 years of financing management experience, primarily with technology companies. Before his current appointment, he served as Chief Financial Officer for Atlas Lifttech, Inc. from 2020 to 2023. His past experience also includes serving as Director of Internal Audit at Intervideo, Inc., prior to its acquisition by Corel, and various senior finance management roles at Fortel, Inc., formerly Zitel Corporation, where he was the Chief Financial Officer from 2000 through 2004. Mr. Dizon began his career at Touche Ross & Co.
AI Analysis | Feedback
The key risks to IRIDEX (IRIX) include its financial viability and profitability, regulatory and technological obsolescence, and intense market competition.
- Financial Viability and Profitability: IRIDEX has demonstrated concerning financial health metrics, including a negative Altman Z-Score of -2.36, which suggests a potential risk of bankruptcy within the next two years. The company has consistently reported quarterly net losses and has a history of burning through cash at "alarming rates." Furthermore, the market has at times valued IRIDEX at roughly its cash on hand, essentially assigning "zero value to the business/assets." Its small market capitalization (ranging from approximately $17 million to $23 million) also exposes it to liquidity risks and high stock price volatility.
- Regulatory and Technological Risks: As a medical technology company operating in the healthcare sector, IRIDEX is inherently exposed to significant regulatory and technological risks. The ophthalmic market is characterized by rapid technological innovation and change, posing a risk that IRIDEX's existing products could become obsolete or be surpassed by new, superior alternatives. Maintaining necessary certifications, such as the CE mark for European markets, is crucial, and any loss of such certification would materially and adversely affect its business.
- Intense Competition: The market for laser systems and delivery devices used in ophthalmic treatment procedures is highly competitive, and this intensity is expected to increase. This competitive pressure can impact IRIDEX's ability to maintain or grow market share, affect pricing power, and necessitate continuous investment in research and development to remain competitive.
AI Analysis | Feedback
AI Analysis | Feedback
IRIDEX Corporation (IRIX) operates within the ophthalmic medical technology sector, providing laser systems and devices for treating a range of sight-threatening eye diseases, including glaucoma, diabetic macular edema (DME), and other retinal disorders, as well as instruments for vitrectomy procedures. The addressable markets for their main products and services are substantial both globally and in the U.S.
Glaucoma Treatment Market
The global market for glaucoma treatment was valued at approximately USD 6.58 billion in 2023 and is projected to reach USD 10.30 billion by 2033, demonstrating a compound annual growth rate (CAGR) of 4.31% from 2027 to 2033. Another estimate places the global market at USD 7.11 billion in 2024, anticipated to grow to USD 11.41 billion in 2033 with a CAGR of 5.4%. For the U.S. specifically, the glaucoma treatment market was valued at USD 2.19 billion in 2024 and is projected to grow to approximately USD 2.78 billion by 2034, with a CAGR of 2.30%. In 2022, the U.S. market for glaucoma treatment held the highest share among the 7MM (United States, EU4, UK, and Japan), with an estimated net sales revenue of USD 2,571 million.
Retinal Disorder Treatment Market (including Diabetic Macular Edema and other Retinal Diseases)
The global retinal disorder treatment market, which encompasses conditions like diabetic macular edema, proliferative diabetic retinopathy, macular holes, retinal tears, and detachments, was estimated at USD 13.69 billion in 2023 and is expected to reach USD 25.69 billion by 2030, growing at a CAGR of 9.4% from 2024 to 2030. Another report valued the global retinal disorder treatment market at USD 18.3 billion in 2024, with a projected CAGR of 6.7% from 2025 to 2034. The U.S. retinal disorder treatment industry alone was valued at USD 7.1 billion in 2024 and is projected to reach USD 13.1 billion by 2034.
More specifically for Diabetic Macular Edema (DME), the global treatment market is valued at approximately USD 5 billion in 2024 and is projected to reach USD 8 billion by 2030, exhibiting a CAGR of over 7%. The DME treatment market is also expected to reach USD 6.7 billion by 2025, with a CAGR of 5.1%. In 2023, the diabetic macular edema market size reached USD 5.4 billion and is expected to reach USD 7.5 billion by 2034, growing at a CAGR of 3.07%.
Vitrectomy Devices Market
The global vitrectomy devices market, which includes instruments used in vitrectomy procedures, was valued at USD 1.28 billion in 2023 and is projected to reach USD 1.87 billion by 2030, growing at a CAGR of 5.3% from 2024 to 2030. Other estimates indicate the market will grow from USD 1.72 billion in 2025 to USD 2.48 billion by 2031 at a 6.29% CAGR, or from USD 1.9 billion in 2026 to USD 2.51 billion by 2031 at a 5.72% CAGR. North America held the largest share of the global vitrectomy devices market, accounting for 35.9% in 2023.
AI Analysis | Feedback
IRIDEX Corporation (IRIX) is poised for future revenue growth over the next 2-3 years, driven by several strategic initiatives and market recoveries.
- Growth in Cyclo G6 Probe Sales: The company anticipates continued recovery and growth in sales of its Cyclo G6 probes, which are a key consumable for its glaucoma treatment systems. IRIDEX reported a recovery trend in probe sales in Q2 2024 and saw a significant increase in Cyclo G6 probe sales in Q4 2025, with 15,800 probes sold compared to 13,300 in the prior year quarter. Annual probe sales also increased to 57,700 units in 2025 from 55,400 in 2024. This indicates a sustained demand for these critical components.
- Recovery and Growth in Capital Equipment Sales: After experiencing softness and elongated purchasing cycles in prior periods, IRIDEX expects a resurgence in sales of its capital equipment, specifically Pascal and Cyclo G6 glaucoma laser systems. The company noted a recovery of capital equipment in its retina business and Cyclo G6 systems in the glaucoma business in Q2 2024. This trend continued into 2025, with higher Pascal system sales driving retina product revenue growth and an increase in Cyclo G6 Glaucoma Laser System sales, reaching 133 units in 2025 compared to 125 in 2024.
- Improved Commercial Efficiency and Operational Profitability: IRIDEX has emphasized focused cost reductions, gross margin expansion, and improved commercial efficiency, which are expected to bolster its financial position and support revenue growth. The company anticipates achieving positive adjusted EBITDA for the full year 2025 and reported positive cash flow in Q4 2025. These operational improvements provide a more stable foundation for sustained investments in growth initiatives.
- International Market Expansion and Supply Chain Optimization: Despite facing some international delays and tariff disputes, IRIDEX continues to market its products globally through a network of independent distributors in over 100 countries. Management has highlighted efforts to address supply challenges and international regulatory hurdles, indicating that overcoming these issues will unlock further growth opportunities in international markets.
- Launch and Adoption of New Retina Laser Products: In January 2024, IRIDEX launched new Iridex 532 and Iridex 577 Lasers in the U.S. market. These new product introductions for the retina segment are expected to contribute to future revenue as they gain market adoption and expand the company's offering in treating diabetic macular edema and other retinal diseases.
AI Analysis | Feedback
Share Issuance
- In March 2021, Iridex issued common shares to Topcon Corporation, which acquired an approximately 10.4% equity stake by purchasing $10 million of Iridex common shares at $6.18 per share.
Inbound Investments
- Iridex received $19.5 million in cash in March 2021 as part of a strategic collaboration with Topcon Corporation.
Outbound Investments
- As part of the strategic collaboration with Topcon Corporation in March 2021, Iridex acquired Topcon's PASCAL® product line.
Capital Expenditures
- Iridex reported capital expenditures of $13,000 in the third quarter of 2025.
- For the last 12 months (around March 2025), capital expenditures were -$46,000, contributing to a free cash flow of -$3.99 million.
Peer Outperformance in Life Sciences Tools & Services
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| IRIX | IRIDEX | -2.7% | -3.3x | -43.7% | -69.5% | -90.2% | — |
| CRL | Charles River Laboratories International | -1.4% | -56.0x | 78.9% | 40.3% | -36.8% | +53pp |
| ILMN | Illumina | 0.3% | 43.9x | 133.2% | 84.9% | -43.3% | +47pp |
| BIO | Bio-Rad Laboratories | -2.1% | 45.3x | 32.5% | 5.3% | -52.1% | +38pp |
| AVTR | Avantor | -2.9% | -18.2x | 24.2% | -28.0% | -63.8% | +26pp |
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 16.2% | 43.2% | 90.1% | CAH 392% · MCK 346% · COR 168% |
| Managed Health Care | 8 | 40.4% | -5.3% | 2.3% | OSCR 84% · HQY 56% · ELV 17% |
| Health Care Services | 20 | 21.1% | 37.6% | -0.3% | HIMS 239% · RDNT 173% · DGX 76% |
| Health Care Facilities | 24 | 6.0% | 6.5% | -4.5% | NHC 271% · THC 261% · ENSG 129% |
| Health Care Equipment | 50 | -2.7% | -0.2% | -21.1% | POCI 11050% · UFPT 341% · GKOS 222% |
| Pharmaceuticals | 62 | -10.5% | 14.8% | -38.6% | LQDA 2472% · INDV 1099% · ETON 1051% |
| Health Care Supplies | 12 | 14.1% | -8.9% | -39.7% | LNTH 287% · HAE 54% · MMSI 20% |
| Life Sciences Tools & Services ← | 109 | 4.3% | -11.3% | -68.4% | SNWV 1757% · MEDP 231% · NTRA 199% |
| Health Care Technology | 21 | -25.8% | -52.6% | -79.2% | SPOK 68% · HSTM 3% · VEEV -13% |
| Biotechnology | 364 | 0.6% | -21.7% | -79.4% | CELZ 1280% · DNTH 1221% · ELVN 1069% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| IRIDEX Earnings Notes | 12/16/2025 | |
| Is IRIDEX Stock Built to Withstand a Pullback? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 13.64 |
| Mkt Cap | 1.6 |
| Rev LTM | 815 |
| Op Inc LTM | -2 |
| FCF LTM | -2 |
| FCF 3Y Avg | -5 |
| CFO LTM | 57 |
| CFO 3Y Avg | -4 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.6% |
| Rev Chg 3Y Avg | 2.3% |
| Rev Chg Q | 8.1% |
| QoQ Delta Rev Chg LTM | 1.9% |
| Op Inc Chg LTM | 21.0% |
| Op Inc Chg 3Y Avg | 20.0% |
| Op Mgn LTM | -0.7% |
| Op Mgn 3Y Avg | -5.1% |
| QoQ Delta Op Mgn LTM | 0.7% |
| CFO/Rev LTM | 6.9% |
| CFO/Rev 3Y Avg | -2.6% |
| FCF/Rev LTM | -0.7% |
| FCF/Rev 3Y Avg | -5.0% |
Segment Financials
Revenue by Segment| $ Mil | 2026 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Retina | 30 | 28 | 29 | 31 |
| Cyclo G6 | 14 | 13 | 13 | 14 |
| Other | 9 | 8 | 9 | 9 |
| Total | 53 | 49 | 52 | 54 |
| $ Mil | 2011 | 2010 | 2001 | 2000 |
|---|---|---|---|---|
| Ophthalmology | 23 | 22 | ||
| Aesthetics | 8 | 8 | ||
| Unallocated | -28 | -28 | ||
| Dermatology Medical Devices | 4 | |||
| Ophthalmology Medical Devices | 14 | |||
| Laser Medical Device | 3 | |||
| Laser Research | 0 | |||
| Total | 3 | 3 | 18 | 3 |
Price Behavior
| Market Price | $0.67 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 02/16/1996 | |
| Distance from 52W High | -57.1% | |
| 50 Days | 200 Days | |
| DMA Price | $0.81 | $1.09 |
| DMA Trend | down | down |
| Distance from DMA | -17.6% | -38.8% |
| 3M | 1YR | |
| Volatility | 52.3% | 67.0% |
| Downside Capture | 39.68 | 118.75 |
| Upside Capture | -239.10 | 30.90 |
| Correlation (SPY) | -3.9% | 18.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -1.70 | -0.58 | 0.24 | 0.74 | 0.94 | 0.85 |
| Up Beta | 3.36 | 1.40 | 0.96 | 0.28 | 0.20 | 0.45 |
| Down Beta | 0.68 | 1.68 | 1.91 | 2.79 | 2.54 | 1.46 |
| Up Capture | -409% | -273% | -119% | -33% | 9% | 20% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 9 | 10 | 22 | 48 | 106 | 317 |
| Down Capture | -568% | 13% | 24% | 114% | 105% | 100% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 12 | 27 | 34 | 55 | 112 | 358 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IRIX | |
|---|---|---|---|---|
| IRIX | -48.2% | 67.0% | -0.70 | - |
| Sector ETF (XLV) | 24.4% | 16.1% | 1.16 | 2.6% |
| Equity (SPY) | 16.9% | 12.9% | 0.94 | 18.9% |
| Gold (GLD) | 19.1% | 29.3% | 0.60 | -4.5% |
| Commodities (DBC) | 46.3% | 20.6% | 1.73 | 7.4% |
| Real Estate (VNQ) | 4.9% | 13.6% | 0.10 | 3.2% |
| Bitcoin (BTCUSD) | -30.6% | 44.3% | -0.70 | 7.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IRIX | |
|---|---|---|---|---|
| IRIX | -38.5% | 68.7% | -0.41 | - |
| Sector ETF (XLV) | 6.4% | 15.2% | 0.24 | 10.8% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 20.3% |
| Gold (GLD) | 19.1% | 18.8% | 0.83 | 2.3% |
| Commodities (DBC) | 11.2% | 19.5% | 0.45 | 2.3% |
| Real Estate (VNQ) | 1.1% | 18.8% | -0.05 | 15.7% |
| Bitcoin (BTCUSD) | 12.5% | 52.5% | 0.42 | 13.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IRIX | |
|---|---|---|---|---|
| IRIX | -27.0% | 71.6% | -0.13 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.51 | 15.7% |
| Equity (SPY) | 15.1% | 18.0% | 0.72 | 21.5% |
| Gold (GLD) | 12.1% | 16.4% | 0.61 | 3.6% |
| Commodities (DBC) | 8.3% | 18.1% | 0.37 | 8.8% |
| Real Estate (VNQ) | 4.4% | 20.7% | 0.18 | 18.0% |
| Bitcoin (BTCUSD) | 62.6% | 66.2% | 1.02 | 8.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/21/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/18/2026 | -15.8% | -23.0% | -29.9% |
| 5/19/2026 | -4.8% | -1.9% | 7.6% |
| 3/26/2026 | -26.7% | -27.4% | -20.0% |
| 1/12/2026 | 28.7% | 22.6% | 24.3% |
| 11/12/2025 | -7.0% | -0.2% | 3.4% |
| 8/12/2025 | -9.2% | -11.2% | 5.4% |
| 5/13/2025 | -9.1% | -7.3% | -14.5% |
| 3/27/2025 | 13.1% | 7.6% | 47.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 12 | 14 |
| # Negative | 16 | 16 | 14 |
| Median Positive | 8.2% | 7.1% | 7.6% |
| Median Negative | -9.1% | -9.5% | -15.0% |
| Max Positive | 44.4% | 95.5% | 81.8% |
| Max Negative | -28.3% | -30.0% | -31.2% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/18/2026 | -15.8% | -23.0% | -29.9% |
| 5/19/2026 | -4.8% | -1.9% | 7.6% |
| 3/26/2026 | -26.7% | -27.4% | -20.0% |
| 1/12/2026 | 28.7% | 22.6% | 24.3% |
| 11/12/2025 | -7.0% | -0.2% | 3.4% |
| 8/12/2025 | -9.2% | -11.2% | 5.4% |
| 5/13/2025 | -9.1% | -7.3% | -14.5% |
| 3/27/2025 | 13.1% | 7.6% | 47.2% |
| 1/14/2025 | 2.9% | 4.8% | -6.4% |
| 11/12/2024 | 34.0% | 26.2% | 22.0% |
| 8/8/2024 | -0.5% | 1.1% | 5.3% |
| 5/14/2024 | -14.0% | -12.7% | -30.5% |
| 11/14/2023 | 6.8% | 7.4% | 38.4% |
| 8/10/2023 | -28.3% | -30.0% | -4.1% |
| 5/11/2023 | -0.5% | 1.1% | -16.2% |
| 3/9/2023 | -9.1% | -7.1% | -6.2% |
| 1/10/2023 | -4.0% | 0.4% | 7.5% |
| 11/10/2022 | 5.0% | -0.6% | 6.4% |
| 8/15/2022 | -13.3% | -17.5% | -25.8% |
| 5/12/2022 | 2.5% | -3.1% | -15.5% |
| 3/10/2022 | -6.2% | 5.3% | -0.9% |
| 1/11/2022 | 9.6% | -3.7% | -9.1% |
| 11/12/2021 | -10.7% | -17.7% | -31.2% |
| 8/12/2021 | 20.9% | 12.0% | 11.8% |
| 5/11/2021 | 4.1% | 6.9% | 6.4% |
| 3/22/2021 | -0.4% | -7.9% | 3.6% |
| 1/11/2021 | 44.4% | 95.5% | 81.8% |
| 11/9/2020 | 2.1% | -12.0% | -0.5% |
| SUMMARY STATS | |||
| # Positive | 12 | 12 | 14 |
| # Negative | 16 | 16 | 14 |
| Median Positive | 8.2% | 7.1% | 7.6% |
| Median Negative | -9.1% | -9.5% | -15.0% |
| Max Positive | 44.4% | 95.5% | 81.8% |
| Max Negative | -28.3% | -30.0% | -31.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/18/2026 | 10-Q |
| 03/31/2026 | 05/19/2026 | 10-Q |
| 12/31/2025 | 04/02/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/20/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/18/2026 | 10-Q |
| 03/31/2026 | 05/19/2026 | 10-Q |
| 12/31/2025 | 04/02/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/20/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/15/2022 | 10-K |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 08/12/2021 | 10-Q |
| 03/31/2021 | 05/12/2021 | 10-Q |
| 12/31/2020 | 03/23/2021 | 10-K |
| 09/30/2020 | 11/10/2020 | 10-Q |
| 06/30/2020 | 08/10/2020 | 10-Q |
| 03/31/2020 | 05/12/2020 | 10-Q |
| 12/31/2019 | 03/13/2020 | 10-K |
| 09/30/2019 | 11/08/2019 | 10-Q |
Recent Forward Guidance
Updated 8/19/2026Latest: Q2 2026 Earnings Reported 8/18/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 51.00 Mil | 52.00 Mil | 53.00 Mil | 0 | Affirmed | Guidance: 52.00 Mil for 2026 | |
| 2026 Adjusted Operating Expenses | Reported | 19.00 Mil | 19.25 Mil | 19.50 Mil | 0 | Affirmed | Guidance: 19.25 Mil for 2026 | |
Prior: Q1 2026 Earnings Reported 5/19/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 51.00 Mil | 52.00 Mil | 53.00 Mil | Affirmed | Guidance: 52.00 Mil for 2026 | ||
| 2026 Adjusted Operating Expenses | Reported | 19.00 Mil | 19.25 Mil | 19.50 Mil | Affirmed | Guidance: 19.25 Mil for 2026 | ||
Insider Activity
Updated 9/16/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 9162026 | 0.63 | 7,900 | 4,977 | 116,743 | Form |
| 2 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 9142026 | 0.65 | 2,354 | 1,530 | 115,314 | Form |
| 3 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 9102026 | 0.68 | 5,100 | 3,468 | 119,035 | Form |
| 4 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 8242026 | 0.75 | 1,300 | 973 | 123,240 | Form |
| 5 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 8242026 | 0.75 | 5,368 | 4,025 | 127,447 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 9162026 | 0.63 | 7,900 | 4,977 | 116,743 | Form |
| 2 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 9142026 | 0.65 | 2,354 | 1,530 | 115,314 | Form |
| 3 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 9102026 | 0.68 | 5,100 | 3,468 | 119,035 | Form |
| 4 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 8242026 | 0.75 | 1,300 | 973 | 123,240 | Form |
| 5 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 8242026 | 0.75 | 5,368 | 4,025 | 127,447 | Form |
| 6 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 6152026 | 1.14 | 975 | 1,110 | 154,821 | Form |
| 7 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 6122026 | 1.14 | 1,675 | 1,909 | 153,900 | Form |
| 8 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 6092026 | 1.12 | 2,400 | 2,688 | 149,324 | Form |
| 9 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 6082026 | 1.15 | 2,521 | 2,899 | 150,564 | Form |
| 10 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 6032026 | 1.17 | 2,400 | 2,808 | 150,233 | Form |
| 11 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 5262026 | 1.00 | 5,004 | 5,004 | 126,004 | Form |
| 12 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 3092026 | 1.26 | 1,110 | 1,399 | 152,460 | Form |
| 13 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 2172026 | 1.34 | 2,200 | 2,942 | 160,326 | Form |
| 14 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 2122026 | 1.43 | 1,500 | 2,145 | 168,297 | Form |
| 15 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 2102026 | 1.46 | 1,000 | 1,460 | 169,637 | Form |
| 16 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 2032026 | 1.38 | 2,500 | 3,450 | 158,962 | Form |
| 17 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 1282026 | 1.46 | 1,300 | 1,898 | 162,920 | Form |
| 18 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 1262026 | 1.52 | 1,243 | 1,889 | 162,494 | Form |
| 19 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 1232026 | 1.48 | 5,221 | 7,716 | 156,156 | Form |
| 20 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 1212026 | 1.50 | 2,159 | 3,233 | 150,417 | Form |
| 21 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 1212026 | 1.50 | 2,100 | 3,147 | 147,294 | Form |
| 22 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 1162026 | 1.43 | 3,496 | 5,006 | 137,732 | Form |
| 23 | Moore, William M | Direct | Buy | 12182025 | 1.01 | 2,000 | 2,020 | 254,040 | Form | |
| 24 | Moore, William M | Direct | Buy | 12162025 | 0.00 | 20,000 | Form | |||
| 25 | Moore, William M | Direct | Buy | 12152025 | 0.00 | 20,920 | Form | |||
| 26 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 12152025 | 0.97 | 2,365 | 2,296 | 89,988 | Form |
| 27 | Moore, William M | Direct | Buy | 12152025 | 0.00 | 9,080 | Form | |||
| 28 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 12042025 | 0.95 | 1,584 | 1,498 | 85,439 | Form |
| 29 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 11212025 | 0.96 | 5,760 | 5,530 | 85,187 | Form |
| 30 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 11202025 | 0.96 | 1,000 | 960 | 79,657 | Form |
| 31 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 11192025 | 0.94 | 2,133 | 2,005 | 77,057 | Form |
| 32 | Moore, William M | Direct | Buy | 11182025 | 0.97 | 21,843 | 21,087 | 242,001 | Form | |
| 33 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 11182025 | 0.96 | 3,124 | 2,999 | 76,642 | Form |
| 34 | Moore, William M | Direct | Buy | 11182025 | 0.97 | 28,157 | 27,245 | 221,417 | Form | |
| 35 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 11172025 | 0.88 | 14,769 | 12,997 | 67,513 | Form |
| 36 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 9152025 | 1.36 | 1,450 | 1,975 | 84,359 | Form |
| 37 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 9122025 | 1.35 | 1,250 | 1,682 | 81,418 | Form |
| 38 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 9112025 | 1.34 | 1,500 | 2,010 | 79,395 | Form |
| 39 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 9102025 | 1.37 | 1,500 | 2,055 | 79,118 | Form |
| 40 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 9092025 | 1.40 | 500 | 700 | 78,750 | Form |
| 41 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 9082025 | 1.35 | 1,000 | 1,350 | 75,262 | Form |
| 42 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 9052025 | 1.36 | 1,125 | 1,531 | 74,516 | Form |
| 43 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 9042025 | 1.36 | 625 | 850 | 72,930 | Form |
| 44 | Dizon, Romeo R | Chief Financial Officer | Direct | Buy | 9032025 | 1.34 | 625 | 838 | 71,020 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.